COMPANY

IHP Therapeutics

HQ: San Carlos, CA source · ihptherapeutics.com ↗ · West Coast

Keywords: hematology sickle cell disease

Location: San Carlos, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $433K (NIH grant 5UH3NS134781-03, continuation, notice Sep 7, 2026). NIH RePORTER 5UH3NS134781-03 (Sep 7, 2026)
Evidence (1 event)
- Sep 7, 2026 · NIH RePORTER 5UH3NS134781-03
  Organization: IHP THERAPEUTICS, INC.; City/State: San Carlos, CA; Project number: 5UH3NS134781-03; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 433322; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 7, 2026 Grant Government grant — NIH UH3: $433,322 (annual award, as published), announced Sep 7, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Aug 29, 2025 Grant Government grant — NIH UH3: $982,081 (annual award, as published), announced Aug 29, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Last 2 years.

Sep 7, 2026 Government grant — NIH UH3: $433,322 (annual award, as published), announced Sep 7, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Aug 29, 2025 Government grant — NIH UH3: $982,081 (annual award, as published), announced Aug 29, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Annual award amounts. Total $5.2M.

Jun 14, 2024 NIH award 5R44HL167473-03 FY2024: $1,192,753 awarded for that fiscal year; activity R44 (SBIR); PI PADERI, JOHN; recipient as written: IHP THERAPEUTICS, INC., San Carlos, CA. Development of a novel disease-modifying source ↗
Sep 18, 2023 NIH award 1UG3NS134781-01 FY2023: $2,589,070 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI PADERI, JOHN; recipient as written: IHP THERAPEUTICS, INC., San Carlos, CA. A novel glycan-based selectin and co source ↗
Aug 18, 2023 NIH award 4R44HL167473-02 FY2023: $1,117,633 awarded for that fiscal year; activity R44 (SBIR); PI PADERI, JOHN; recipient as written: IHP THERAPEUTICS, INC., San Carlos, CA. Development of a novel disease-modifying source ↗
Mar 5, 2023 NIH award 1R44HL167473-01 FY2023: $301,480 awarded for that fiscal year; activity R44 (SBIR); PI PADERI, JOHN; recipient as written: IHP THERAPEUTICS, INC., San Carlos, CA. Development of a novel disease-modifying gl source ↗